1. GOLD Executive Committee.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease(updated 2013).
[2]
2. Yao H, Rahman I.Role of histone deacetylase 2 in epigenetics and cellular senescence:implications in lung inflammaging and COPD.Am J Physiol Lung Cell Mol Physiol, 2012, 303:L557-L566.
[3]
3. Qu Y, Yang Y, Ma D, et al.Expression level of histone deacetylase 2 correlates with occurring of chronic obstructive pulmonary diseases.Mol Biol Rep, 2013, 40:3995-4000.
[4]
4. Barnes PJ.Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease.J Allergy Clin Immunol, 2013, 131:636-645.
[5]
5. Hakim A, Adcock IM, Usmani OS.Corticosteroid resistance and novel anti-inflammatory therapies in chronic obstructive pulmonary disease:current evidence and future direction.Drugs, 2012, 72:1299-1312.
[6]
6. Mroz RM, Noparlik J, Chyczewska E, et al.Molecular basis of chronicin flammation in lung diseases:new therapeutic approach.J Physiol Pharmacol, 2007, Suppl 5(Pt 2):453-460.
[7]
8. Barnes PJ, Adcock IM, Ito K.Histone acetylation and deacetylation:importance in inflammatory lung diseases.Eur Respir J, 2005, 25:552-563.
[8]
13. Ito K, Yamamura S, Essilfie-Quaye S, et al.Histone deacetylase 2 mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression.J Exp Med, 2006, 203:7-13.
[9]
14. Ito K, Hanazawa T, Tomita K, et al.Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression:role of tyrosine nitration.Biochem Biophys Res Commun, 2004, 315:240-245.
[10]
17. Barnes PJ, Ito K, Adcock IM.Corticosteroid resistance in chronic obstructive pulmonary disease:inactivation of histone deacetylase.Lancet, 2004, 363:731-733.
[11]
21. Marwick JA, Chung KF.Glucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis, 2010, 5:297-309.
[12]
7. Gong F, Miller KM.Mammalian DNA repair:HATs and HDACs make their mark through histone acetylation.Mutat Res, 2013, 750:23-30.
10. Ito K, Ito M, Elliott WM, Cosio B, et al.Decreased histone deacetylase activity in chronic obstructive pulmonary disease.N Engl J Med, 2005, 352:1967-1976.
[15]
11. Rajendrasozhan S, Yao H, Rahman I.Current perspectives on role of chromatin modifications and deacetylases in lung inflammation in COPD.COPD, 2009, 6:291-297.
[16]
12. Chen Y, Huang P, Ai W, et al.Histone deacetylase activity is decreased in peripheral blood monocytes in patients with COPD.J Inflamm(Lond), 2012, 23:9-10.
[17]
15. Marwick JA, Kirkham PA, Stevenson CS, et al.Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs.Am J Respir Cell Mol Biol, 2004, 31:633-642.
[18]
16. Marwick JA, Ito K, Adcock IM, et al.Oxidative stress and steroid resistance in asthma and COPD:pharmacological manipulation of HDAC-2 as a therapeutic strategy.Expert Opin Ther Targets, 2007, 11:745-755.
[19]
18. Calverley PM, Anderson JA, Celli B, et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.N Engl J Med, 2007, 356:775-789.
[20]
19. Yang IA, Fong KM, Sim EH, et al.Inhaled corticosteroids for stable chronic obstructive pulmonary disease.Cochrane Database Syst Rev, 2012, 11:7.
[21]
20. Winkler AR, Nocka KH, Sulahian TH, et al.In vitro modeling of human alveolar macrophage smoke exposure:enhanced inflammation and impaired function.Exp Lung Res, 2008, 34:599-629.
[22]
22. Chung KF, Marwick JA.Molecular mechanisms of oxidative stress in airways and lungs with reference to asthma and chronic obstructive pulmonary disease.Ann N Y Acad Sci, 2010, 1203:85-91.
[23]
23. Cosio BG, Iglesias A, Rios A, et al.Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD.Thorax, 2009, 64:424-429.
[24]
24. Barnes PJ.Theophylline.Am J Respir Crit Care Med, 2013, 188:901-906.
[25]
25. Spagnolo P, Fabbri LM, Bush A.Long-term macrolide treatment for chronic respiratory disease.Eur Respir J, 2013, 42:239-251.
[26]
26. Albert RK, Connett J, Bailey WC, et al.Azithromycin for prevention of exacerbations of COPD.N Engl J Med, 2011, 365:689-698.
[27]
27. Pomares X, Montón C, Espasa M, et al.Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations.Int J Chron Obstruct Pulmon Dis, 2011, 6:449-456.
[28]
28. Mammen MJ, Sethi S.Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease.Pol Arch Med Wewn, 2012, 122:54-59.
[29]
29. Kobayashi Y, Wada H, Rossios C, et al.A novel macrolide/fluoroketolide, solithromycin(CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition.Br J Pharmacol, 2013, 169:1024-1034.
[30]
30. Kumar D, Kumar M, Saravanan C, et al.Curcumin:a potential candidate for matrix metalloproteinase inhibitors.Expert Opin Ther Targets, 2012, 16:959-972.
[31]
31. Biswas S, Hwang JW, Kirkham PA, et al.Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease.Curr Med Chem, 2013, 20:1496-1530.
